Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (TWEYES)
A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Studietyp
Studietyp
Inskrivning (Faktisk)
Inskrivning
Fas
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Borgomanero, Italien, 28021
- Novartis Investigative Site
-
Galliate, Italien, 28066
- Novartis Investigative Site
-
Napoli, Italien, 80131
- Novartis Investigative Site
-
Napoli, Italien, 80132
- Novartis Investigative Site
-
Napoli, Italien, 80138
- Novartis Investigative Site
-
Pozzuoli, Italien, 80078
- Novartis Investigative Site
-
-
AL
-
Alessandria, AL, Italien, 15100
- Novartis Investigative Site
-
Casale Monferrato, AL, Italien, 15033
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italien, 60126
- Novartis Investigative Site
-
-
BA
-
Acquaviva delle Fonti, BA, Italien, 70021
- Novartis Investigative Site
-
Putignano, BA, Italien, 70017
- Novartis Investigative Site
-
Terlizzi, BA, Italien, 70038
- Novartis Investigative Site
-
-
BG
-
Bergamo, BG, Italien, 24127
- Novartis Investigative Site
-
-
BL
-
Belluno, BL, Italien, 32100
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Italien, 40138
- Novartis Investigative Site
-
-
BS
-
Brescia, BS, Italien, 25123
- Novartis Investigative Site
-
Desenzano del Garda, BS, Italien, 25015
- Novartis Investigative Site
-
-
BZ
-
Bolzano, BZ, Italien, 39100
- Novartis Investigative Site
-
-
CA
-
Cagliari, CA, Italien, 09124
- Novartis Investigative Site
-
-
CB
-
Larino, CB, Italien
- Novartis Investigative Site
-
-
CE
-
Caserta, CE, Italien, 81100
- Novartis Investigative Site
-
-
CH
-
Chieti, CH, Italien, 66100
- Novartis Investigative Site
-
-
CN
-
Ceva, CN, Italien, 12073
- Novartis Investigative Site
-
Cuneo, CN, Italien, 12100
- Novartis Investigative Site
-
-
CO
-
Como, CO, Italien, 22100
- Novartis Investigative Site
-
San Feramo Della Battaglia, CO, Italien, 22020
- Novartis Investigative Site
-
-
CT
-
Acireale, CT, Italien, 95024
- Novartis Investigative Site
-
Catania, CT, Italien, 95124
- Novartis Investigative Site
-
Catania, CT, Italien, 95123
- Novartis Investigative Site
-
-
CZ
-
Catanzaro, CZ, Italien, 88100
- Novartis Investigative Site
-
-
FC
-
Forlì, FC, Italien, 47100
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italien, 44100
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Italien, 71100
- Novartis Investigative Site
-
San Giovanni Rotondo, FG, Italien, 71013
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italien, 16132
- Novartis Investigative Site
-
Genova, GE, Italien, 16153
- Novartis Investigative Site
-
Rapallo, GE, Italien, 16035
- Novartis Investigative Site
-
-
KR
-
Crotone, KR, Italien, 88074
- Novartis Investigative Site
-
-
LE
-
Tricase, LE, Italien, 73039
- Novartis Investigative Site
-
-
LT
-
Terracina, LT, Italien, 04019
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Italien, 98125
- Novartis Investigative Site
-
Milazzo, ME, Italien, 98057
- Novartis Investigative Site
-
-
MI
-
Cinisello Balsamo, MI, Italien, 20092
- Novartis Investigative Site
-
Legnano, MI, Italien, 20025
- Novartis Investigative Site
-
Milano, MI, Italien, 20132
- Novartis Investigative Site
-
Milano, MI, Italien, 20122
- Novartis Investigative Site
-
Milano, MI, Italien, 20123
- Novartis Investigative Site
-
Milano, MI, Italien, 20100
- Novartis Investigative Site
-
Milano, MI, Italien, 20142
- Novartis Investigative Site
-
Rozzano, MI, Italien, 20089
- Novartis Investigative Site
-
Vizzolo Predabissi, MI, Italien, 20070
- Novartis Investigative Site
-
-
NU
-
Nuoro, NU, Italien, 08100
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italien, 90127
- Novartis Investigative Site
-
Palermo, PA, Italien, 90146
- Novartis Investigative Site
-
-
PC
-
Piacenza, PC, Italien, 29100
- Novartis Investigative Site
-
-
PD
-
Camposampiero, PD, Italien, 35012
- Novartis Investigative Site
-
Monselice, PD, Italien, 35043
- Novartis Investigative Site
-
Padova, PD, Italien, 35128
- Novartis Investigative Site
-
Padova, PD, Italien, 35100
- Novartis Investigative Site
-
-
PE
-
Pescara, PE, Italien, 65124
- Novartis Investigative Site
-
-
PG
-
Citta' di Castello, PG, Italien, 06012
- Novartis Investigative Site
-
Foligno, PG, Italien, 06034
- Novartis Investigative Site
-
Perugia, PG, Italien, 06100
- Novartis Investigative Site
-
-
PN
-
Pordenone, PN, Italien, 33170
- Novartis Investigative Site
-
-
PR
-
Parma, PR, Italien, 43100
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Italien, 27100
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria, RC, Italien, 89124
- Novartis Investigative Site
-
-
RE
-
Correggio, RE, Italien, 42015
- Novartis Investigative Site
-
Reggio Emilia, RE, Italien, 42123
- Novartis Investigative Site
-
-
RM
-
Civitavecchia, RM, Italien, 00053
- Novartis Investigative Site
-
Roma, RM, Italien, 00168
- Novartis Investigative Site
-
Roma, RM, Italien, 00161
- Novartis Investigative Site
-
Roma, RM, Italien, 00133
- Novartis Investigative Site
-
Roma, RM, Italien, 00184
- Novartis Investigative Site
-
Roma, RM, Italien, 00189
- Novartis Investigative Site
-
Roma, RM, Italien, 00186
- Novartis Investigative Site
-
-
RN
-
Riccione, RN, Italien, 47838
- Novartis Investigative Site
-
-
SA
-
Eboli, SA, Italien, 84025
- Novartis Investigative Site
-
Salerno, SA, Italien, 84131
- Novartis Investigative Site
-
-
SO
-
Sondrio, SO, Italien, 23100
- Novartis Investigative Site
-
-
SP
-
Sarzana, SP, Italien, 19038
- Novartis Investigative Site
-
-
SS
-
Sassari, SS, Italien, 07100
- Novartis Investigative Site
-
-
SV
-
Savona, SV, Italien, 17100
- Novartis Investigative Site
-
-
TA
-
Taranto, TA, Italien, 74100
- Novartis Investigative Site
-
-
TE
-
Teramo, TE, Italien, 64100
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italien, 10122
- Novartis Investigative Site
-
Torino, TO, Italien, 10153
- Novartis Investigative Site
-
Torino, TO, Italien, 10152
- Novartis Investigative Site
-
-
TR
-
Terni, TR, Italien, 05100
- Novartis Investigative Site
-
-
TS
-
Trieste, TS, Italien, 34129
- Novartis Investigative Site
-
-
TV
-
Conegliano, TV, Italien, 31015
- Novartis Investigative Site
-
Treviso, TV, Italien, 31100
- Novartis Investigative Site
-
-
UD
-
Udine, UD, Italien, 33100
- Novartis Investigative Site
-
-
VA
-
Busto Arsizio, VA, Italien, 21052
- Novartis Investigative Site
-
Somma Lombardo, VA, Italien, 21019
- Novartis Investigative Site
-
Varese, VA, Italien, 21100
- Novartis Investigative Site
-
-
VI
-
Santorso, VI, Italien, 36014
- Novartis Investigative Site
-
Vicenza, VI, Italien, 36100
- Novartis Investigative Site
-
-
VR
-
Legnago, VR, Italien, 37045
- Novartis Investigative Site
-
Negrar, VR, Italien, 37024
- Novartis Investigative Site
-
Verona, VR, Italien, 37126
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
Male or female patients aged 50 years or above Willing and capable to provide informed written consent Eye(s) eligible for ranibizumab treatment, with a BCVA below 2/10 due to wet AMD and/or Second eye eligible for ranibizumab treatment, with first eye treated (currently or previously) with ranibizumab, whichever BCVA. In bilateral wAMD patients, the second eye can be included only if the first eye has been treated at least 14 days before with ranibizumab
Exclusion Criteria:
Active intraocular inflammation (grade trace or above) in either eye Any ocular or periocular active infection (current or suspected), e.g. conjunctivitis, keratitis, scleritis, uveitis, endophtalmitis, in either eye Risk factors for retinal pigment epithelial tear (including pigment epithelial retinal detachment) Ocular disorders that may confound interpretation of results compromise visual acuity or require medical or surgical intervention during the study period including cataract, retinal vascular occlusion, retinal detachment or macular hole Uncontrolled glaucoma in either eye (IOP ≥ 30 mmHg on medication or according to investigator's judgment) History of vitrectomy in the study eye History of stroke or transient ischemic attack Systemic treatment with any VEGF inhibitor in the 90 days prior to study enrollment Ocular treatment of the study eye with any anti-angiogenic drugs within 1 month prior to study enrollment Any intraocular surgery in the study eye within 28 days prior to enrollment Women of childbearing potential UNLESS using effective contraception during treatment Pregnant or lactating women Simultaneous participation in a study that includes administration of any investigational drug Known hypersensitivity to ranibizumab or any component of the ranibizumab formulation Inability to comply with study procedures.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Experimentell: Ranibizumab
Administered as an Intravitreal injection
|
All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e.
stable VA for three consecutive monthly assessments performed while on ranibizumab treatment).
Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity.
Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
|
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants With Systemic Drug-related Adverse Events
Tidsram: Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
|
Number of Eyes With Ocular Drug-related Adverse Events
Tidsram: Baseline to Month 12
|
Monitoring and recording all adverse events, including serious adverse events.
|
Baseline to Month 12
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Number of Ranibizumab Injections
Tidsram: Baseline to month 12
|
Baseline to month 12
|
|
|
Time Interval Between Injections in Bilateral Disease
Tidsram: Baseline to month 12
|
Mean number of days between two consecutive injections per eye
|
Baseline to month 12
|
|
Mean Number of Injections Per Patient
Tidsram: Baseline to month 12
|
Number of injections per patient
|
Baseline to month 12
|
Samarbetspartners och utredare
Sponsor
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Studiestart
Primärt slutförande (Faktisk)
Primärt slutförande
Avslutad studie (Faktisk)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- CRFB002AIT02
- 2013-003333-15 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .